$0.16
3.81%
Nasdaq, Nov 22, 03:30 pm CET
ISIN
US75973T1016
Symbol
RNLX

Renalytix Plc - ADR Stock price

$0.16
+0.01 6.40% 1M
-0.27 62.47% 6M
-0.23 59.08% YTD
-0.35 68.74% 1Y
-19.17 99.17% 3Y
-13.34 98.82% 5Y
-13.34 98.82% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.81%
ISIN
US75973T1016
Symbol
RNLX

Key metrics

Market capitalization $15.16m
Enterprise Value $22.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.57
P/S ratio (TTM) P/S ratio 6.45
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -18.70%
Revenue (TTM) Revenue $2.35m
EBIT (operating result TTM) EBIT $-24.09m
Free Cash Flow (TTM) Free Cash Flow $-24.45m
Cash position $910.00k
EPS (TTM) EPS $-0.51
P/E forward negative
P/S forward 3.24
EV/Sales forward 4.12
Short interest 1.52%
Show more

Is Renalytix Plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Renalytix Plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Renalytix Plc - ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Renalytix Plc - ADR:

Buy
100%

Financial data from Renalytix Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.35 2.35
19% 19%
100%
- Direct Costs 2.05 2.05
18% 18%
87%
0.30 0.30
25% 25%
13%
- Selling and Administrative Expenses 17 17
36% 36%
709%
- Research and Development Expense 7.42 7.42
44% 44%
316%
-24 -24
39% 39%
-1,012%
- Depreciation and Amortization 0.30 0.30
41% 41%
13%
EBIT (Operating Income) EBIT -24 -24
39% 39%
-1,025%
Net Profit -28 -28
36% 36%
-1,193%

In millions USD.

Don't miss a Thing! We will send you all news about Renalytix Plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Renalytix Plc - ADR Stock News

Neutral
GlobeNewsWire
5 months ago
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of prec...
Neutral
GlobeNewsWire
5 months ago
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
Neutral
GlobeNewsWire
6 months ago
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage

Company Profile

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.

Head office United Kingdom
CEO James McCullough
Founded 2018
Website renalytix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today